Patten Group Inc. increased its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 66.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 556 shares of the medical instruments supplier’s stock after purchasing an additional 221 shares during the period. Patten Group Inc.’s holdings in C.R. Bard were worth $106,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Leucadia National Corp acquired a new position in shares of C.R. Bard during the 2nd quarter worth about $13,184,000. Vivaldi Asset Management LLC acquired a new stake in C.R. Bard in the 2nd quarter valued at about $57,965,000. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in C.R. Bard by 12.3% in the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 16,951 shares of the medical instruments supplier’s stock valued at $5,358,000 after acquiring an additional 1,859 shares during the last quarter. Artemis Investment Management LLP raised its holdings in C.R. Bard by 33.4% in the 2nd quarter. Artemis Investment Management LLP now owns 41,313 shares of the medical instruments supplier’s stock valued at $13,068,000 after acquiring an additional 10,354 shares during the last quarter. Finally, Sirios Capital Management L P acquired a new stake in C.R. Bard in the 2nd quarter valued at about $71,393,000. Hedge funds and other institutional investors own 79.35% of the company’s stock.

Shares of C.R. Bard, Inc. (NYSE BCR) opened at $332.00 on Thursday. The stock has a market cap of $24,206.82, a P/E ratio of 28.68, a PEG ratio of 2.54 and a beta of 0.52. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. C.R. Bard, Inc. has a 1-year low of $216.55 and a 1-year high of $337.73.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.96 by $0.06. The business had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The business’s revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.64 EPS. research analysts forecast that C.R. Bard, Inc. will post 11.89 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be issued a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.31%. C.R. Bard’s dividend payout ratio is currently 13.70%.

BCR has been the subject of a number of recent research reports. Cowen reiterated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a report on Friday, November 3rd. Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a report on Thursday, October 26th. Jefferies Group reiterated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a report on Thursday, September 14th. Barclays increased their price objective on shares of C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a report on Monday, November 6th. Finally, ValuEngine downgraded shares of C.R. Bard from a “buy” rating to a “hold” rating in a report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has given a strong buy rating to the company. C.R. Bard has an average rating of “Hold” and a consensus price target of $303.50.

In other news, VP Betty D. Larson sold 5,906 shares of the firm’s stock in a transaction that occurred on Friday, October 20th. The shares were sold at an average price of $330.16, for a total transaction of $1,949,924.96. Following the completion of the sale, the vice president now owns 10,753 shares in the company, valued at approximately $3,550,210.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Timothy P. Collins sold 8,388 shares of the firm’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $322.00, for a total transaction of $2,700,936.00. The disclosure for this sale can be found here. Insiders have sold a total of 206,637 shares of company stock valued at $67,650,121 in the last 90 days. Insiders own 0.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “C.R. Bard, Inc. (BCR) Shares Bought by Patten Group Inc.” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/14/c-r-bard-inc-bcr-shares-bought-by-patten-group-inc.html.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.